Phathom Pharmaceuticals, Inc.
NASDAQ•PHAT
CEO: Ms. Terrie J. Curran
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2019-10-25
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Contact Information
100 Campus Drive, Suite 102, Florham Park, NJ, 07932, United States
877-742-8466
Market Cap
$827.07M
P/E (TTM)
-5.4
24.5
Dividend Yield
--
52W High
$18.31
52W Low
$7.61
52W Range
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data